Literature DB >> 29316235

Antithrombin concentrate use in disseminated intravascular coagulation of sepsis: meta-analyses revisited.

C J Wiedermann1.   

Abstract

Recently, two meta-analyses examined the effect of antithrombin on mortality in patients with sepsis and disseminated intravascular coagulation (DIC) with diverging results. In the meta-analysis observing no significant survival effect of antithrombin, the results of a large trial were included under the assumption that all 2314 participants of the trial had sepsis and DIC, which according to post hoc analyses was not the case. To the other meta-analysis reporting beneficial effect, the same trial contributed only those 229 patients that had confirmed sepsis-induced DIC. Replacing the mixed sepsis patient group with and without DIC with the group of sepsis patients with confirmed DIC provides evidence for a beneficial intervention effect of antithrombin also in the meta-analysis that reported no beneficial effect of antithrombin on mortality. This revised result does not change the overall conclusion that the quantity and quality of evidence supporting the use of antithrombin in sepsis patients with DIC is low.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  antithrombin; cochrane; disseminated intravascular coagulation; meta-analysis; risk of bias; sepsis

Mesh:

Substances:

Year:  2018        PMID: 29316235     DOI: 10.1111/jth.13950

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  10 in total

Review 1.  Signaling pathways and intervention therapies in sepsis.

Authors:  Yun-Yu Zhang; Bo-Tao Ning
Journal:  Signal Transduct Target Ther       Date:  2021-11-25

Review 2.  Coagulopathy in COVID-19.

Authors:  Ka U Lio; Parth Rali
Journal:  Lung India       Date:  2021-03

3.  Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation.

Authors:  Toshiaki Iba; Makoto Arakawa; Yoshifumi Ohchi; Takao Arai; Koichi Sato; Hideo Wada; Jerrold H Levy
Journal:  Clin Appl Thromb Hemost       Date:  2018-09-09       Impact factor: 2.389

Review 4.  Anticoagulant therapy for septic coagulopathy and disseminated intravascular coagulation: where do KyberSept and SCARLET leave us?

Authors:  Christian J Wiedermann
Journal:  Acute Med Surg       Date:  2020-01-16

Review 5.  A Systematic Summary of Systematic Reviews on Anticoagulant Therapy in Sepsis.

Authors:  Shuhei Murao; Kazuma Yamakawa
Journal:  J Clin Med       Date:  2019-11-04       Impact factor: 4.241

6.  Antithrombin use and mortality in patients with stage IV solid tumor-associated disseminated intravascular coagulation: a nationwide observational study in Japan.

Authors:  Kohei Taniguchi; Hiroyuki Ohbe; Kazuma Yamakawa; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga
Journal:  BMC Cancer       Date:  2020-09-09       Impact factor: 4.430

Review 7.  Antithrombin and Its Role in Host Defense and Inflammation.

Authors:  Christine Schlömmer; Anna Brandtner; Mirjam Bachler
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

8.  The Necessity of Individualized Treatment for Sepsis-Associated Disseminated Intravascular Coagulation by Infected Organ.

Authors:  Makoto Kobayashi; Yoshimatsu Ehama; Suguru Hirayama
Journal:  Open Access Emerg Med       Date:  2022-04-07

9.  A question is "what are the optimal targets for anticoagulant therapies?"

Authors:  Nobuyuki Yokoyama; Shunsuke Takaki; Masashi Yokose; Kaori Kuwabara; Akiko Anzai; Takako Hamada; Shizuka Kashiwagi; Kenta Okamura; Yoh Sugawara; Takahisa Goto
Journal:  J Intensive Care       Date:  2020-02-14

Review 10.  Recent advances in the research and management of sepsis-associated DIC.

Authors:  Toshiaki Iba; Jean Marie Connors; Isao Nagaoka; Jerrold H Levy
Journal:  Int J Hematol       Date:  2021-01-02       Impact factor: 2.490

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.